There is one clinical trial.

Clinical Trials

1 Use of a Medical Device, Kerecis Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa

Kerecis Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf (the "Device"). An 81-patient double blind clinical trial will be conducted to evaluate the Device against placebo in COVID-19 positive, symptomatic patients in Iceland. Immediate access to COVID-19 patients is available through a well-organized COVID-19 outpatient follow-up clinic. Up to 81 patients with mild to moderate symptoms of COVID-19 will be recruited (so called "higher end of the low risk group"). These patients will be positive for COVID-19, be symptomatic with upper respiratory symptoms, but without involvement of the entire respiratory system. The patients will be randomized to receive treatment with the Study Device or to receive placebo. 54 patients will be randomized into the Study Device group and 27 patients into the Control group. The Study Device group will be split into two with 27 patients administering the Device to both the oral and nasal passages and 27 patients to the oral only. Patients will administer Study Device or Control for 14 days and will have their symptoms recorded until no further symptoms are reported, up to a maximum of 28 days follow-up.

NCT04357990 COVID-19 Device: Kerecis Oral and Nasal Spray Other: Placebo

No related HPO nodes (Using clinical trials)